SCHEMBL4356535

SCHEMBL4356535

NC(=O)[C@H](CCC(=O)O)N(C(=O)c1ccc(-c2ccccc2)cc1)C1CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 2/20 0.43
CHRM4 P08173 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
FFAR1 O14842 3/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
HIF1A Q16665 1/20 0.41
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
MCHR1 Q99705 1/20 0.39
USP30 Q70CQ3 2/20 0.39
MMP8 P22894 2/20 0.38
MMP13 P45452 2/20 0.38
SMYD3 Q9H7B4 1/20 0.38
MMP2 P08253 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.37
OXTR P30559 1/20 0.37
ADAMTS4 O75173 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4364691 0.94 MMP12 (0.41) MMP12CHRM4SMN1; SMN2FFAR1RAB9A
SCHEMBL5652194 0.82 MMP12 (0.41) MMP12SMN1; SMN2FFAR1RAB9ALMNA
SCHEMBL5651552 0.80 TRPM8 (0.45) MMP12SMN1; SMN2FFAR1RAB9ALMNA
SCHEMBL2249544 0.74 MMP12 (0.39) MMP12CHRM4SMN1; SMN2FFAR1RAB9A
SCHEMBL4365442 0.74 MMP12 (0.42) MMP12SMN1; SMN2FFAR1RAB9ALMNA
SCHEMBL2247308 0.73 TRPM8 (0.43) MMP12SMN1; SMN2FFAR1RAB9ALMNA
SCHEMBL4357426 0.73 MMP12 (0.43) MMP12SMN1; SMN2FFAR1RAB9ALMNA
SCHEMBL2246642 0.73 MMP12 (0.41) MMP12SMN1; SMN2FFAR1RAB9ALMNA
SCHEMBL16147559 0.73 PPARD (0.49) CHRM4
SCHEMBL2245053 0.72 MMP12 (0.41) MMP12SMN1; SMN2FFAR1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 MMP12 54/4885CHRM4 3807/4885SMN1; SMN2 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.